Schema-Root.org logo

 

  cross-referenced news and research resources about

 Pfizer Inc.

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Wed. November 20, 2019

-
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors head into next week with a bit of improved visibility after tariff exemptions were spelled ...
The AdComm outcome isn't just good news for Pfizer, which is looking to expand its blockbuster further after December's psoriatic arthritis nod. It's also good news for would-be competitors in the JAK inhibitor class, such as AbbVie's upadacitinib and Gilead's filgotinib, Porges figures. “We regard this vote as ...

US regulatory advisors are backing use of Pfizer's JAK inhibitor Xeljanz to treat adults with moderately to severely active ulcerative colitis (UC). The US Food and Drug Administration's Gastrointestinal Drugs Advisory Committee voted unanimously (15-0) in favour of marketing clearance for the drug in this ...
Pfizer Inc. announced a positive outcome from today's U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee (GIDAC) meeting. The GIDAC met to discuss Pfizer's supplemental New Drug Application (sNDA) for XELJANZ® (tofacitinib), which is currently under review by the ...
In fact, Pfizer is exclusively responsible for the discovery and development of the rheumatoid arthritis drug Xeljanz and assumed all the risk in applying insights from the publicly available, basic research results of an outstanding researcher at the National Institutes of Health to help advance an existing ...
Pfizer has been slowly but surely backing out of its $635 million armed antibody tech deal with CytomX in the last few months, and during the biotech's financials posted late yesterday, the final nail was drilled into this fruitless pact. In 2013, the big pharma teamed up with the South San Francisco-based ...

Pfizer (PFE) is the second largest major drug manufacturer by market capitalization. Out of 28 competitors, they have the 9th highest PE and 16th highest forward PE. But these numbers are skewed; more than half of the major drug manufacturers have current or projected losses, giving them a current and ...
The South San Francisco-based biotech says that Pfizer $PFE notified them yesterday that they are dropping out of the Probody deal, discarding its latest two targets after dumping the first on EGFR and never going after the fourth. The deal, which started out with a $25 million upfront payment and a large ...
Chicago, IL – March 6, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Pfizer Inc. PFE, Verizon ...
Pfizer (PFE) reported slightly higher-than-expected fourth-quarter results and issued 2018 tax-rate guidance 500 basis points below our expectations, which will likely lead to an increase in our fair value estimate relatively close to the current stock price. Pfizer's largely flat total revenue in the quarter despite ...
England's National Health Service (NHS) might be able to reclaim £502 million in drug costs from Pfizer if the pharma giant exhausts all legal avenues to maintain its patent on the pain medication pregabalin. Prescriptions of Pfizer's branded version of the drug – Lyrica – increased by 25% after doctors ...
Federated Investors turns 63 on Oct. 1 and the financial-services giant, with about $400 billion in assets under management, has gone a lot further than most ventures formed by high-school buddies. Federated (ticker: FII) is also the home of one of the market's most respected observers, Stephen Auth, chief ...
In late February 2018, an article posted to “alternative health” blog HealthNutNews.com began circulating, leading readers to believe that the vice president of the pharmaceutical giant Pfizer had “blown the whistle” on Gardasil, a vaccine that protects against human papillomavirus, an umbrella term for ...
Gains in technology, banks and industrial companies drove U.S. stocks higher Wednesday as shareholders sized up the most recent company earnings news. Consumer goods companies lagged the most. The most recent gains put the market on track to recoup some of its losses from a day earlier.
The FDA approval is likely to give AstraZeneca a competitive advantage in the lung cancer treatment market over Merck KgA & Pfizer, who received rejections for a similar treatment. AstraZeneca received FDA approval for Imfinzi in non-small cell lung cancer one day after Merck KgA and Pfizer received a ...
Shares of Pfizer Inc. (PFE) ended the trading day Wednesday at $35.76, representing a move of -0.69%, or $0.25 per share, on volume of 23.96 million shares. Pfizer Inc is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and ...
Pfizer Inc. (PFE) is an interesting player in the Healthcare space, with a focus on Drug Manufacturers – Major. The stock has been active on the tape, currently trading at $36.01, down from yesterday's close by -0.69%. Given the stock's recent action, it seemed like a good time to take a closer look at the ...

Sue Dillon isn't the only Big Pharma R&D exec to make news this week after making the switch to biotech. Cambridge, MA-based biotech standout Magenta Therapeutics has just recruited Pfizer vet John Davis as their new chief medical officer. Davis had been the senior vice president and head of early ...
Shares of Pfizer Inc. (PFE) ended the trading day Tuesday at $36.01, representing a move of -0.69%, or $0.25 per share, on volume of 25.62 million shares. Pfizer Inc is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and ...
And that expansion -- the most visible part of an ongoing $147 million investment by Pfizer Inc. -- is a very good thing for Portage and Kalamazoo County, local leaders say. "It's important because it shows us long-term that Pfizer plans to be here for a long time," said Portage Mayor Patricia Randall. Portage ...
In 4Q17, Pfizer (PFE) generated revenues of $13.7 billion, which was ~1% higher on a YoY (year-over-year) basis and 4% higher quarter-over-quarter. In fiscal 2017, Pfizer reported revenues of $52.5 billion, which represents a ~1% decline YoY. In 4Q17, Pfizer reported net income of $12.3 billion, compared with $775 ...
The company unveiled it's new facility Tuesday and now they are ready to fill it with new employees. U.S. Representative Fred Upton and Portage Mayor Patricia Randall helped cut the ribbon at Pfizer's new 98,500 square foot warehouse Tuesday. The facility cost $147 million to build. The building will be ...
Pfizer has filed for approval of its third-generation ALK inhibitor lorlatinib, a follow-up to its first-generation Xalkori product which is facing increasing competition. The pharma company has submitted lorlatinib in Europe, the US and Japan as a second-line treatment for AL-positive non-small cell lung cancer ...
Pfizer (NYSE:PFE) is up 1% premarket on light volume on the heels of its announcement that its marketing applications in the U.S., Europe and Japan seeking approval for lorlatinib to treat ALK-positive non-small cell lung cancer (NSCLC) have been accepted for review. The FDA's action date under ...
In fiscal 2017, Pfizer's (PFE) oncology business generated revenues of $6.06 billion, which reflected ~33% growth on a YoY (year-over-year) basis. In the US and international markets in 2017, Pfizer's oncology business generated revenues of $4.36 billion and $1.67 billion, respectively—compared to ...
Between 2005 and 2010, Pfizer introduced two drugs that went on to become blockbusters. From 2011 through 2016, the company launched five blockbuster drugs. Over the past five years, Pfizer grew earnings by around 4% annually. During that period, the stock gained close to 30%. That might not seem ...
(NYSE:LLY) and Pfizer Inc. (NYSE:PFE), side by side to see which comes out on top. Both big U.S. pharma stocks generate strong cash flows and they aren't shy about returning plenty of that cash to shareholders. Let's take a look at what's driving profits for both companies to see which stock is poised to ...
You could almost use the case for Pfizer to argue why GlaxoSmithKline is a stock to buy. Over the past few years, GSK has been weighed down by falling sales for older drugs. The company has been hit especially hard by declining revenue for its top-selling product, Seretide/Advair. The likely entrance of a ...
AbbVie, Pfizer in another close TV ad spending race to kick off 2018. by Beth Snyder Bulik |. Feb 7, 2018 9:31am. TV watching. Pharma TV advertising kicked off the new year with $138 million in January spending. (StockSnap/CCO). Share Facebook Twitter LinkedIn Email Print. It's a new year in the TV ad spending game in ...
Pfizer Inc. (NYSE:PFE) stock has struggled since the release of its January 30 earnings report. Despite beats on top- and bottom-line numbers, the stock has been caught up in the swoon that's hit the overall market in the last week. As a result, the stock has fallen 13% in the previous week alone. However ...
Shares of Pfizer (NYSE:PFE) are down 2% year to date despite the large sell-off shares have undergone over the past few days. Nevertheless I felt its recent earnings numbers gave a lot of room for encouragement. We hold this underlying in our portfolio as a low beta stock which has strong competitive ...
“New target ideas and novel chemical matter are critical to our success in bringing new therapies to patients around the world,” said Yuan-Hua Ding, head of Pfizer's external science and innovation unit, in a release. “This collaboration represents our worldwide commitment to partnering with companies ...
Any Pfizer Inc. (NYSE:PFE) shareholders that were hoping for a bidding war for its consumer health division have to be at least a bit disappointed. How so? By the time bids were due last week, only two parties were still interested. To that end, given the names that walked away from the process without ...
Pfizer $PFE and J&J $JNJ have come down to the wire with pivotal data on nonmetastatic prostate cancer. And there are billions of dollars in revenue on the line here. Both companies posted their abstracts being reviewed at ASCO's Genitourinary Cancers Symposium Monday evening. And while scientists ...
With the consumer health market changing, some bidders have reportedly gotten cold feet about bidding for Pfizer's or German Merck's units. ... as leader in a deal to buy Merck KGaA's consumer businesses and Pfizer is said to have only two interested parties, GlaxoSmithKline and Reckitt Benckiser Group, ...
Pfizer forecast 2018 profit and revenue well ahead of analysts' estimates on Tuesday as it expects to benefit from reduced tax rate following the recent changes to the U.S. tax code, and recorded an $11 billion gain from the overhaul. The drugmaker also beat fourth-quarter profit and revenue estimates on ...
Pfizer beats the Street's fourth-quarter earnings expectations and lays out plans for the new tax law. Pfizer also says its adjusted tax rate will be about 17 percent next year. It anticipates a $15 billion tax bill to repatriate its overseas cash. CEO Ian Reed says Pfizer is on track to make a decision on its ...
Investors who are keeping close eye on the stock of Pfizer Inc. (NYSE:PFE) established that the company was able to keep return on investment at 6.91 in the trailing twelve month while Reuters data showed that industry's average stands at 14.96 and sector's optimum level is 14.27. Pfizer Inc. (PFE) have ...
Johnson & Johnson (JNJ 2) has pulled out of the race to buy the Pfizer (PFE 3) consumer health business, leaving GlaxoSmithKline (GSK 4) and Reckitt Benckiser (RBGPF 5) among those preparing bids, according to Reuters 6. Bidders have until Feb. 1 to submit their non-binding offers for the unit, which ...
We expect Pfizer, Inc. PFE to beat expectations when it reports fourth-quarter and full year 2017 results on Jan 30, before the market opens. Last quarter, the company delivered a positive earnings surprise of 3.08%. The pharma giant has a fairly decent record of earnings surprises. The company's earnings ...
Inspired by the Merck system and advances in flow chemistry, researchers at Pfizer aimed to build an even more flexible high-throughput system for chemical reaction discovery. Damith Perera, Paul Richardson, Neal W. Sach, and colleagues at Pfizer now report having developed an automated instrument ...
Johnson & Johnson has pulled out of the race to buy Pfizer's consumer health business, leaving GlaxoSmithKline and Reckitt Benckiser among those preparing bids, according to sources familiar with the matter. Bidders have until Feb. 1 to submit their non-binding offers for the unit, which makes Advil ...
Pfizer $PFE is barreling forward on its plans to recreate Roche's stalwart cancer drugs, announcing positive data this morning for its Rituxan copycat called PF-05280586. Considering Roche's $RHHBY recent backlash to biosimilar competition, it's possible that Pfizer will continue to poke the rather litigious ...
Pfizer said several weeks ago that the FDA had updated the status of its troubled Kansas fill-finish plant, paving the way for drug approvals, and sure enough this week Novartis announced an FDA nod for its Copaxone generic being produced there. But a recently released document from the last inspection ...
Pfizer opens first part of Michigan site expansion, hiring 200. by Eric Palmer |. Feb 15, 2018 10:04am. Pfizer HQ. Pfizer, which is spending about $150 million on its manufacturing site in Kalamazoo, Michigan, said a new warehouse there will be operational next month. (Image: Pfizer). Share Facebook Twitter LinkedIn Email ...
Strong free cash flow allows Pfizer to return a significant amount of capital back to shareholders through dividends (3.66% annual yield) and share repurchases. Pfizer's stock trades at a discount based on historical multiples, a comparables analysis, and a discounted cash flow model. Pfizer's sales have ...
Updated results from the Phase 3 PALOMA-2 study evaluating Pfizer's (NYSE:PFE) IBRANCE (palbociclib), combined with Novartis' FEMARA (letrozole), in patients with ER+/HER2- metastatic breast cancer continue to show a durable treatment benefit. The data will be presented on December 8 at the San ...
The Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia today launched 'Tune in to AFib, Take Note of Stroke Risk' to educate the estimated nearly seven million Americans in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their ...
Pfizer Inc. (NYSE: PFE) today announced updated progression-free survival (PFS) results from the Phase 3 PALOMA-2 trial reinforcing the clinical benefit of IBRANCE® (palbociclib) combined with letrozole. The data, which will be presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) on ...
Villagers of Ringaskiddy, County Cork, Ireland, say air pollution from a factory that produces the erectile dysfunction drug Viagra are affecting the menfolk. "One whiff and you're stiff," local bartender Debbie O'Grady told the Sunday Times. If it's not the fumes emanating from Pfizer's plant, then it's the water ...


 

news and opinion


 


 


 


 


schema-root.org

     pfizer
       brands

pharmaceutical industry:
     allergan
     ariad
     astrazeneca
     baxter
     eli lilly
     glaxosmithkline
     merck
     mylan
     novartis
     pfizer
     products
     purdue pharma
     research
     takeda
     teva
     upjohn
     valeant